A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf.
Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant
2015
Arquivos Brasileiros de Oftalmologia
Preserved Fulltext
a major contributor to decreased visual acuity (VA) secondary to uveitis, and is usually treated with systemic, periocular, or intraocular ste roids (1, 2) . The dexamethasone 0.7-mg implant (Ozurdex® Allergan, Inc., CA, USA) is an innovative slow-release system that is biodegradable. It can be implanted through an injection system, and implantation can be performed on an outpatient basis. Dexamethasone has potent anti-inflammatory properties and a history of favorable effects for the treatment
doi:10.5935/0004-2749.20150049
pmid:26222112
fatcat:hyk7w657crghvmq55eybliouhi